In Vivo IGF-1R Molecular Imaging Using [68Ga]- Labelling Anti-IGF-1R Affibody Molecule
Targeted Molecular Imaging of [68Ga]- Labelling Anti-IGF-1R Affibody Molecule in IGF-1R Overexpression Cancer Patients (Such as Colon Cancer、NSCLC and Gliomas)and Healthy Volunteers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Yingying Sun
- Phone Number: 18846797135
- Email: 505679386@qq.com
Study Locations
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150028
- Recruiting
- TOF-PET/CT/MR center of the Fourth Hospital of Harbin Medical University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Colon cancer, NSCLC and gliomas patients with pathological and gene detection results and did not receive any treatment
- More than 18 years old
- A life expectancy of at least 12 weeks
- Presence of a malignant lesion within the chest of at least 0.5 cm diameter as measured by computed tomography (CT)
- Written informed consent
Exclusion Criteria:
- Could not get pathological and gene detection results
- Pregnancy
- do not want to write informed consent。
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 68Ga-NODAGA-ZIGF-1R:4:40:IGF-1R+++
Patients in this group had IGF-1R overexpression tumors and did not receive any treatment before this study.
|
No Intervention
|
|
Experimental: 68Ga-NODAGA-ZIGF-1R:4:40:IGF-1R++
Patients in this group had IGF-1R moderate expression tumors and did not receive any treatment before this study.
|
No Intervention
|
|
Experimental: 68Ga-NODAGA-ZIGF-1R:4:40:IGF-1R+
Patients in this group had IGF-1R low expression tumors and did not receive any treatment before this study.
|
No Intervention
|
|
Experimental: 68Ga-NODAGA-ZIGF-1R:4:40:healthy volunteers
Patients in this group who are healthy volunteer.
|
No Intervention
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
tumor SUV value of 68Ga-NODAGA-ZIGF-1R:4:40 PET/CT Imaging
Time Frame: after scanning(at time of imaging)
|
To quantify the accumulation, a volume of interest using a 3D sphere, was placed over the tumor, lymph nodes and distant metastases avoiding necrosis, blood vessels and normal tissues as much as possible on a workstation (Advantage Workstation 4.6; GE Healthcare).
The maximum standard uptake value (SUVmax) normalized to body weight (kBq/mL) was calculated within the region of interest.
|
after scanning(at time of imaging)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Baozhong Shen, The Fourth Hospital of Harbin Medical University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 14403
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.